Revenue: As of FY2025 Q4, the actual value is USD 17.1 M.EBIT: As of FY2025 Q4, the actual value is USD 5.76 M.<h3>Fourth Quarter 2025 Financial Highlights</h3><ul><li>Gross Margins: Gross margins were 82.4% in the fourth quarter of 2025, a roughly 2,400 basis point year-over-year increase compared to 58.0% in the fourth quarter of 2024. </li><li>Operating Income: Operating income was $4.6 million in the fourth quarter of 2025, compared to an operating loss of - $1.7 million in the fourth quarter of 2024. </li><li>Cash Balance: The company’s cash balance was $6.4 million as of December 31, 2025. </li><li>Total Operating Expenses: Total operating expenses were $12.5 million for the fourth quarter of 2025, compared with $14.3 million for the fourth quarter of 2024. </li><li>Selling, General and Administrative Expenses: Selling, general and administrative expenses were $8.7 million for the fourth quarter of 2025, compared with $8.2 million for the fourth quarter of 2024, mainly driven by legal costs. </li><li>Net Income (Loss): Net income was $5.6 million in the fourth quarter of 2025, compared with a net loss of - $1.4 million for the prior-year quarter. </li><li>Adjusted EBITDA: Adjusted EBITDA was $4.9 million in the fourth quarter of 2025, compared with - $1.4 million for the fourth quarter of 2024. </li><li>Adjusted EBITDA Margin: The Adjusted EBITDA margin was 28.8% for the fourth quarter of 2025, compared to -10.9% for the fourth quarter of 2024. </li></ul><h3>Full Year 2025 Financial Results</h3><ul><li>Gross Profit Margin: Gross profit margin was 73.7% for the full year 2025, compared to 50.1% for the prior year, with cost of goods sold related party decreasing 43% year over year. </li><li>Total Operating Expenses: Total operating expenses were $53.1 million for 2025, compared with $54.5 million for the same period in 2024, with increased legal expense offset by reduced operational cost. </li><li>Net Loss: Net loss was - $10.5 million for 2025, compared to a loss of - $17.7 million in the prior year. </li><li>Adjusted EBITDA: Adjusted EBITDA was - $10.6 million for 2025, compared with - $15.3 million for 2024. </li><li>Adjusted EBITDA Margin: The Adjusted EBITDA margin was -25.4% for the full year 2025, compared to -40.9% for 2024. </li></ul><h3>Cash Flow Highlights (Full Year)</h3><ul><li>Cash Flows Used in Operating Activities: Cash flows used in operating activities were - $13,361 thousand for 2025, compared to - $10,270 thousand for 2024. </li><li>Cash Flows Provided by (Used in) Investing Activities: Cash flows provided by investing activities were $2,998 thousand for 2025, compared to - $3 thousand for 2024, including $3,000 thousand in proceeds from the sale of an asset held for sale in 2025. </li><li>Cash Flows Provided by Financing Activities: Cash flows provided by financing activities were $10,850 thousand for 2025, compared to $14,835 thousand for 2024, including $10,850 thousand from the issuance of Series C preferred stock in 2025. </li><li>Net Increase in Cash and Cash Equivalents: The net increase in cash and cash equivalents was $487 thousand for 2025, compared to $4,562 thousand for 2024. </li><li>Cash, Cash Equivalents and Restricted Cash, at Year-End: Cash, cash equivalents and restricted cash at year-end totaled $6,592 thousand for 2025, compared to $6,105 thousand for 2024. </li></ul><h3>Operational Highlights</h3><ul><li>Biofrontera Inc. announced positive results from its Phase 2b clinical trial evaluating Ameluz® topical gel for moderate to severe acne vulgaris (AV). </li><li>The company received FDA’s filing acceptance of the supplemental New Drug Application (sNDA) for Ameluz® Photodynamic Therapy (PDT) for superficial basal cell carcinoma (sBCC). </li><li>Positive and statistically significant top-line results were reported from its Phase 3 clinical trial for Ameluz® PDT for mild to moderate actinic keratoses (AKs) on the extremities, neck, and trunk. </li><li>A database lock was completed for a Phase 1 pharmacokinetics study required for FDA filing. </li><li>Biofrontera Inc. closed the purchase of all Ameluz and RhodoLED US Assets from Biofrontera AG, which reduced the earnout structure payment rate from 25%–35% to 12%–15% of U.S. net sales. </li><li>The company received the final $2.5 million of an $11 million financing round. </li><li>Xepi antibiotic cream was divested to Pelthos Pharmaceuticals for $3 million at closing, $1 million upon commercial availability, and up to $6 million in milestone payments. </li></ul><h3>Outlook / Guidance</h3>Biofrontera Inc. expects the full annualized benefits of its strategic transaction to be realized in 2026, which will lead to a materially strengthened cost profile. The company anticipates a PDUFA date for sBCC in September 2026. Management believes these factors will contribute to moving towards sustained profitability and cash flow breakeven in 2026.

BIOFRONTERA INC C/WTS 27/10/2026 (TO PUR COM) | 8-K: FY2025 Q4 Revenue: USD 17.1 M